• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    uniQure (QURE) Could Be 66% Undervalued On Earnings Pullback

    Simply Wall St·11/06/2026 06:30:05
    Listen to the news

    uniQure (QURE) put fresh numbers on the table with third quarter 2026 earnings, reporting US$5.2 million in revenue and a net loss of US$61.22 million, including a loss per share of US$0.88.

    uniQure’s share price has come under pressure around these results, with the stock falling 8.8% on the day and 16.9% over the past week, while the 1 year total shareholder return is down 23.6% compared with a very large 3 year total shareholder return gain of about 24x. This suggests recent momentum is fading after a strong earlier run as investors reassess both earnings risk and the value they place on the AMT-130 pipeline news.

    Scan beyond uniQure and this earnings-driven pullback to compare it with a curated set of beaten-down quality plays in our 42 high quality undervalued stocks.

    After a sharp pullback from a very large 3 year gain, uniQure now sits at a level where investors have to ask a blunt question: Is most of the AMT-130 optimism already priced in, or is the remaining upside still ahead?

    Most Popular Narrative: 66% Undervalued

    On the most followed view of uniQure, a fair value of about $62 sits far above the recent $21.01 close. This puts the entire AMT-130 debate front and center for anyone treating this pullback as an opportunity or a warning.

    The potential accelerated approval for AMT-130 in treating Huntington's disease could significantly boost future revenues as it would be one of the first disease-modifying treatments available for this condition.

    Expansion of the clinical pipeline with new studies in refractory temporal lobe epilepsy, Fabry disease, and SOD1-ALS could lead to additional revenue streams if these treatments are successful and commercialized.

    See why 12 investors see uniQure as 66% undervalued.

    Result: Fair Value of $62.42 (UNDERVALUED)

    Still, the AMT-130 approval path could be disrupted by mixed four year data and by any manufacturing or supply setbacks for uniQure’s outsourced production model.

    Find out about the key risks to this uniQure narrative.

    Next Steps

    Sentiment on uniQure is split, with sharp recent losses set against a very large multi year gain. Act quickly and weigh both sides of the story by reviewing the 2 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond uniQure?

    If uniQure has you thinking harder about risk and reward, use this moment to widen your watchlist with a few targeted stock ideas that fit your style.